In tablet manufacturing, direct compression of Longdan Xiegan Powder Veterinary Grade API is constrained by the heterogeneous particle morphology of the multi-botanical milled material. Sieve retention profiling under ChP 2020 General Chapter 0912 should be completed before tooling selection because residual stem fibre from Gentiana scabra and seed husk from Plantago asiatica increases lamination risk on rotary presses when the fraction retained on a 150 µm screen exceeds 12% w/w. A robust direct compression blend can be prepared using microcrystalline cellulose PH102 at 38–42% w/w as the primary diluent, dibasic calcium phosphate anhydrous at 14–18% w/w to increase particle density, croscarmellose sodium at 3.0% w/w as disintegrant, and magnesium stearate at 0.8% w/w as lubricant. The API is not a free-flowing crystalline powder; therefore the pre-milled fraction is passed through a 1.0 mm comill with a square-edge screen at low impeller speed to disperse lipid-waxy fractions from Angelica sinensis without generating excessive fines. Final blend loss on drying is maintained at 4.5–6.0% w/w by pre-equilibration in a 25°C/45% RH chamber for 18–24 h when incoming API moisture exceeds 7.0%. Compression on a 19-station rotary press using 19.0 mm × 9.0 mm oval B-tooling is operated at 12–18 kN main compression force, producing tablet hardness of 70–110 N and friability below 1.0% under USP <1216>. Press speeds above 45 rpm are not recommended unless the API fibre fraction is pre-milled to D90 ≤ 74 µm, because viscoelastic rebound of lignified vascular bundles causes edge splitting. A hydroxypropyl methylcellulose film coating of 6 mPa·s viscosity applied at 3.0% w/w weight gain masks bitterness and reduces moisture uptake. Chemical identification of the finished tablet should quantify gentiopicroside and baicalin by HPLC against reference standards using a validated method under VICH GL2; routine release includes heavy metal, arsenic and aristolochic acid I screening as part of botanical identity confirmation. Disintegration time in 900 mL water at 37 ± 2°C under USP <701> should not exceed 30 min unless an enteric design is intentionally selected for ruminant bypass delivery.

What Limits Sterilising Filter Throughput in Aqueous Injection Batches?

For injectable dosage forms, the crude multi-herb powder must be converted into a clarified aqueous extract that is compatible with 0.22 µm sterilising-grade filtration. In a typical process, the powder is refluxed in purified water at 95–98°C for 2 h at a 1:8 w/v drug-to-solvent ratio, followed by a second decoction at 1:6 w/v for 1.5 h. The combined decoction is concentrated under vacuum at −0.08 MPa and 55–65°C until total solids reach 18–22% w/w. Ethanol precipitation is then applied to remove high-molecular-weight polysaccharides, mucilage and denatured proteins; cold ethanol is added to a final concentration of 60% v/v under continuous stirring at ≤ 5°C, precipitating the problematic fraction while retaining gentiopicroside and baicalin in the supernatant. After vacuum filtration and ethanol recovery, the concentrate is reconstituted in water-for-injection and passed through a sequence of 0.45 µm clarification filters followed by a 0.22 µm PVDF filter capsule. A measurable viscosity above 3.5 mPa·s at 25°C is the principal rejection criterion because residual mucilage from Plantago asiatica and Alisma orientale reduces filter throughput to less than 8 L/m² and causes early transmembrane pressure rise beyond 1.0 bar. The solution is aseptically distributed into type I glass vials under ISO 13408-1; terminal steam sterilisation at 121°C for 15 min is generally avoided because precipitation of phenolic-polyphenol complexes darkens the solution and lowers baicalin recovery. Filter integrity is tested under ASTM F838-20 on each batch, and pre-filtration bioburden is controlled under ISO 11737-1:2018 to less than 10 CFU/100 mL. A mandatory safety control is confirmation that Akebia quinata or Clematis armandii caulis is used rather than Aristolochia manshuriensis; HPLC-MS/MS detection of aristolochic acid I in the injection intermediate should adopt a reporting threshold no higher than 0.1 µg/g as an internal batch-release gate. Elemental impurities are risk-assessed under ICH Q3D with specific attention to lead, cadmium and arsenic originating from soil uptake in herbal raw materials. Batch-to-batch variation in pH is adjusted to 5.5–7.0 with dilute sodium hydroxide or hydrochloric acid, and osmolality is corrected with sodium chloride to 280–320 mOsm/kg for parenteral administration in swine and cattle.

Capsule Fill Weight Control Under Variable Botanical Milling Fractions

Unlike crystalline actives, this multi-botanical powder exhibits fill-weight variability in hard-gelatin capsule operations because plate-like leaf fragments and elongated fibre bundles interlock in dosator filling nozzles. The powder fraction passing 150 µm but retained on 75 µm should represent no more than 35% w/w of the capsule blend; higher values create wall friction and erratic plug retention. A direct fill blend may be composed of 55–60% w/w API, mannitol pearlitol SD200 at 20–25% w/w, crospovidone at 2.0% w/w, colloidal silicon dioxide at 0.5% w/w and sodium stearyl fumarate at 1.0% w/w. If API moisture exceeds 6.5% w/w, the material is tray-dried in a forced-air oven at 50°C for 2–3 h; capsule shells are equilibrated at 22°C/35% RH for 24 h to avoid brittle shell fracture. On a tamping-pin encapsulator with size 0 shells, target fill mass is 450 mg ± 5%, and tamping force is set between 120–180 N depending on the milled batch. Vacuum-assisted dosator machines are not recommended when the API fibre content exceeds 10% w/w because plug retention fails intermittently. After encapsulation, metal detection at 0.8 mm ferrous, 1.0 mm non-ferrous and 1.2 mm stainless steel thresholds is deployed to satisfy feed-safety requirements for ruminant and equine applications. Disintegration under USP <701> is controlled with crospovidone rather than sodium starch glycolate, because sodium starch glycolate swells excessively in the presence of acidic herbal polyphenols and can cause cap separation. Analytical release includes total microbial count under USP <2021>, yeast and mould count under USP <2022>, and absence of Escherichia coli and Salmonella under USP <2023>. Heavy metal screening is aligned with Ph. Eur. 5.1.8 using closed-vessel microwave digestion followed by ICP-MS; lead content is not permitted to exceed 5.0 mg/kg, cadmium 1.0 mg/kg, arsenic 2.0 mg/kg and mercury 0.2 mg/kg unless regional veterinary drug law sets a lower bound. The finished capsule is packed in aluminium-aluminium blister under nitrogen purge because oxygen accelerates oxidation of the flavonoid fraction and reduces baicalin assay after 6 months at 30°C/65% RH.

Water-soluble oral powder production for mass medication of poultry drinking water uses a spray-dried or freeze-dried extract intermediate rather than the native milled powder, because insoluble fibre otherwise blocks drinking-line filters and settles in header tanks. The manufacturing route begins with a decoction at 1:10 w/v and 85–95°C for 1.5 h, concentration under vacuum to 25% w/w solids, and spray-drying using a rotary atomiser with inlet temperature 170–180°C and outlet temperature 75–85°C. The spray-dried intermediate is hygroscopic and is immediately blended with anhydrous citric acid at 2.0% w/w as a pH modifier and with maltodextrin DE10–15 at 15–20% w/w to reduce caking. The final water-soluble powder is required to pass a wet-sieving test through 75 µm after reconstitution in 1 L hard water at 25°C; if insoluble residue exceeds 0.5% w/w, the batch is rejected because flock formation obstructs nipple drinkers. Bulk density of the finished powder is controlled between 0.45–0.55 g/cm³ to allow volumetric dosing equipment calibration. Homogeneity after ribbon mixing is evaluated by sampling 10 points and assaying baicalin; the acceptance criterion is relative standard deviation not greater than 5.0%. Packaging in multi-layer paper-foil laminate with heat-sealed seams is required at ≤ 30°C/≤ 35% RH because the spray-dried powder absorbs moisture rapidly above 40% RH. The product is not suitable for use in galvanised drinking-water tanks, because acidic polyphenols from Gardenia jasminoides and Scutellaria baicalensis leach zinc and iron from galvanised surfaces, producing off-colour solutions and metal contamination above feed-water limits.

Ribbon Blender Homogeneity Decay Below 0.5% Dust-Exhaust Collection in Premix Lines

On feed-mill premix lines, the veterinary-grade API is diluted into a carrier system that must resist segregation during transfer, storage and metering into final feed. A common carrier is ground corn cob or rice hull from 300–600 µm particle size, preconditioned with soybean oil at 1.0–1.5% w/w to bind fine particulates. The API is added as a micronised fraction, preferably D90 ≤ 150 µm, but over-milling below 25 µm creates electrostatic dust that is captured by the plant’s dust-extraction system. Dust capture above 0.5% w/w of the nominal API charge reduces homogeneity and shifts marker compound concentration in the finished premix; therefore extraction velocity at the open mixer throat should be set below 0.8 m/s during the first wetting phase. Ribbon mixer tip speed is maintained at 1.2–1.8 m/s, with a fill ratio between 0.55 and 0.70 of gross volume, and mixing time is validated by three-dimensional sampling after 6, 9 and 12 min. A coefficient of variation for baicalin content across 10 sample points of less than 5.0% is the release criterion under EU Regulation 2019/6 Good Manufacturing Practice for feed additives. When the premix is added to compound feed before steam pelleting at 70–85°C, moisture and heat exposure during conditioning should be limited to 20–30 s because baicalin and gentiopicroside are thermally labile in the presence of feed matrices. For mash feed, mineral premix components containing divalent cations such as copper and zinc may complex with polyphenols; therefore separate additive addition lines or chelated mineral sources are preferred. The final premix is packed in multi-wall paper bags with an inner polyethylene liner and stored below 25°C at ≤ 60% RH. Carry-over control is validated by swab testing for marker compounds after flush cycles; equipment-specific limits for residual baicalin are typically set at ≤ 10 mg/kg in the subsequent non-medicated batch unless national feed-safety authority requires lower.

After fluid-bed granulation, the API extract powder is converted into a free-flowing granular dosage form for oral administration via feed top-dressing or drench in calves and pigs. The dry blend consists of 45–50% w/w API extract powder, lactose monohydrate 200 mesh at 35–40% w/w, povidone K30 at 3.0% w/w as binder, and croscarmellose sodium at 2.0% w/w as disintegrant. Granulation is performed in a bottom-spray fluid-bed processor using purified water as the binder solvent; the binder solution is sprayed at 8–12 g/min/kg of batch charge with inlet air temperature of 55–65°C and product temperature of 38–42°C. The endpoint is determined by final moisture content 2.5–3.5% w/w via loss on drying under ChP <0832>, not by fixed spray time, because ambient humidity shifts the drying curve. Dried granules are passed through an oscillator with 0.710 mm mesh; oversize material is dry-sieved rather than re-granulated to avoid binder migration and dark speck formation from concentrated aqueous extract. Bulk density of the finished granule is specified at 0.52–0.60 g/cm³ to ensure reproducible fill into sachets or polypropylene bottles. Hygroscopicity testing under 25°C/75% RH for 48 h is part of packaging selection; uncoated granules gain mass above 5.0% and become sticky. The product is therefore filled in foil-laminated sachets with desiccant when intended for tropical storage. In dissolution testing, the granule is dispersed in 900 mL water at 37 ± 2°C; a validated HPLC marker method for baicalin release is used rather than spectrophotometric total flavonoid because the complex multi-herb matrix interferes at 280 nm. Granule size distribution and moisture content are monitored at batch release under ChP <0982> and ChP <0832>, while microbial enumeration is performed under ChP <1105>. The final granule is intended for mixing into milk replacer or oral drench, not for direct intubation in neonatal animals without prior hydration.

When Oral Solutions Require Preservative Efficacy Under 200-L Polypropylene Totes

Under farm storage conditions, aqueous oral solutions of the veterinary-grade API are susceptible to microbial growth when stored in bulk containers and repeatedly dispensed. The solution is prepared from a clarified water extract rather than the raw powder to prevent nozzle clogging in automatic proportioning pumps. A typical manufacturing sequence includes decoction at 90–100°C for 1 h, cooling to ≤ 10°C for 24 h to settle insoluble particles, filtration through 0.45 µm filters, and dissolution of preservatives and stabilisers. Sodium benzoate at 0.1% w/w and potassium sorbate at 0.1% w/w are used when the product pH is adjusted to 4.5–5.0 with citric acid; above pH 5.5, benzoate loses activity and a different preservative system is required. Preservative effectiveness is challenged under USP <51> against Staphylococcus aureus, Escherichia coli, Pseudomonas aeruginosa, Candida albicans and Aspergillus brasiliensis over 28 days. Bulk storage in 200 L polypropylene totes is acceptable only if the tote material has low oxygen transmission and no recycled content that can leach oleamide slip agents; sorption of baicalin onto polypropylene surfaces is negligible at 4°C–25°C, but long-term contact above 30°C increases loss of the marker by 2–4% over 90 days. The solution is not autoclavable because steam sterilisation precipitates pectin-like polysaccharides; filtration and aseptic filling are used. A pH shift above 5.5 during stability is a critical defect because it indicates fermentation or acid degradation of Gardenia jasminoides iridoid glycosides. The final solution contains 10–15% w/w total solids and is dosed at 1–2 L per 1,000 L drinking water for poultry or 5–10 mL per 20 kg body weight for swine, according to veterinary prescription and local regulations. Labels must state the water withdrawal interval and the diluted solution’s in-use stability; once diluted in drinking water, the solution should be consumed within 6–8 h to prevent microbial regrowth.